A recent study indicates that semaglutide, a GLP-1 drug commonly used for weight loss, may extend lifespan and improve health markers in elderly mice, mimicking the effects of caloric restriction. The findings suggest potential benefits for aging and metabolic health, though fur…
Recent research presented at the Endocrine Society’s ENDO 2026 meeting reveals that individuals taking GLP-1 weight loss medications, such as Ozempic and Wegovy, not only lost wei…
A recent study published in the Journal of Investigative Dermatology suggests that GLP-1 drugs, commonly used for weight loss and diabetes management, may increase the risk of hai…
Recent research indicates that GLP-1 weight-loss drugs, such as semaglutide, may not only aid in weight management but also extend lifespan in older female mice. The study found t…
As metabolic health gains prominence in wellness discussions, the roles of NAD+ and GLP-1 therapies are increasingly scrutinized. This article clarifies how GLP-1 medications like…
This article examines the potential of GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, in treating polyendocrine metabolic ovarian syndrome (PMOS). Experts…
The Medicare GLP-1 Bridge program offers eligible beneficiaries access to weight loss drugs at a reduced cost of $50 per month. However, patients with certain medical conditions,…
GLP-1 receptor agonists, initially developed for diabetes treatment, are being studied for their effects on weight loss and metabolic health in older adults. Recent research sugge…
Researchers at UC Berkeley have discovered that the compound TOFA can enhance energy expenditure and reduce body fat without causing muscle loss in mice. This approach contrasts w…
Recent data indicates a potential decline in obesity rates in the United States, marking a significant shift in a longstanding public health issue. This change coincides with the…
As obesity medications evolve, researchers are exploring new hormone combinations to enhance treatment effectiveness and tolerability. Current studies focus on therapies that not…
Dr. Loren Rourke, a Texas-based breast surgical oncologist, highlights five everyday habits that may help reduce cancer risk and improve health outcomes. While no lifestyle choice…
As 'Ozempic face' becomes a trending concern after weight loss from GLP-1 medications, surgeons adapt by offering innovative treatments to restore youthful facial volume and featu…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…
Eli Lilly is targeting a revenue milestone of $100 billion by fiscal 2026, supported by strong growth in its incretin franchise and a bullish price target of $1,480. The company's…